New Compound Halts Replication of Hepatitis E Virus
Researchers have identified a new compound that effectively stops the replication of the hepatitis E virus (HEV), a discovery that could significantly impact treatment strategies for the disease. The findings, stemming from a recent German study, reveal the virus’s ability to attack not only the liver, but also the kidneys and develop resistance to existing treatments.
The study, conducted by researchers at the Universities of Bochum and Hanover, demonstrated that HEV can invade kidney cells and replicate with the same efficiency as in the liver. This expanded understanding of the virus’s capabilities is crucial, as hepatitis E is a global public health concern, with an estimated 19.47 million acute cases worldwide in 2021, leading to 3,450 deaths, according to the World Health Organization.
A particularly concerning aspect of the research is the virus’s growing resistance to ribavirin, the primary drug currently used to treat HEV. Researchers found that ribavirin’s effectiveness diminishes when the virus resides within kidney cells. This resistance is attributed to differences in the metabolic environment between the liver and kidneys, creating an ideal setting for viral evolution and drug evasion.
“The phenomenon is due to the different metabolic environment between the liver and kidneys, making the latter an ideal environment for the virus to develop and become resistant to treatment,” explained Dr. Andre Gummer, a participant in the study.
The study suggests that the kidneys may serve as a “silent reservoir” for the virus, particularly in chronic infections. So the virus could potentially re-emerge even after initial treatment appears successful. This finding underscores the need for more comprehensive diagnostic and therapeutic approaches to fully eradicate the virus and prevent recurrence.
Whereas HEV typically causes mild symptoms, such as fatigue, nausea, and jaundice, it can lead to acute liver failure in some cases, as noted by the MSD Manual. The virus is primarily transmitted through the fecal-oral route, often via contaminated water. The research team’s findings call for a reevaluation of diagnostic and treatment protocols globally to address this evolving threat.
